Clarify Immune Profiling in Complex Patient Response

Use IsoPlexis’ Precision Profiling™ platform to capture the end function of thousands of single cells using our proprietary IsoCode chip (SCBC), to discover new information in immunotherapy, CAR-T and TCR-T product characterization, predictive clinical biomarkers and checkpoint therapy development. 

Precision Profiling™ has shown that highly functional subsets of cytokine response may provide strong predictive biomarkers of clinical response.

Read More

Isoplexis’ single cell profiling of tumor-infiltrating T-cells has shown the potential to fully characterize patient response to Anti-PD-1 therapy for biomarker development.

Read More

To ensure consistent manufacturing and improved outcomes, T-cell secretomic Precision Profiling™ can determine cellular and donor heterogeneity of CAR-T products.

Read More

Use single-cell profiling to detect engineered T-cell therapy mechanisms, including sources of patient response and relapse, elucidating therapy efficacy.

Read More

Use IsoPlexis' IsoCode chip for single-cell profiling of humanized mice in preclinical translational development of checkpoint inhibitor and cellular therapies.

Read More

Emerging Immune Monitoring Applications

Use IsoPlexis’ Precision Profiling™ platform for vaccine development, treatments for infectious and autoimmune diseases, and profiling tumor inflammation.

Infectious Disease
Vaccine Development

Use single-cell profiling to develop biomarkers indicating the potency and effectiveness of in-development infectious disease vaccines.

Profiling Autoimmune
Disease Progression

Use single-cell polyfunctional profiling to develop biomarkers indicating the progression of autoimmune disease, for better treatment options.

Profiling Tumor
Inflammation

Detect tumor-specific, inflammation-related protein signatures to better understand oncogenic activation and inflammatory signaling.

Preclinical Mouse
Biomarker Studies

Use highly sensitive, single-cell profiling to discover biomarkers relating mouse and human response to preclinically tested immune therapies.

Emerging Cellular Signaling Applications

Use IsoPlexis’ Precision Profiling™ platform for profiling tumor cell metabolomics and analyzing tumor signaling for combination therapies.

Profiling Tumor Cell Metabolomics

Monitor energy transfer and consumption in cancer to determine metabolic phenotypes, providing key information about tumorigenesis.

Tumor Signaling for Combination Therapies

Analyze tumor signaling to predict drug resistance and inform better therapeutic intervention during preclinical drug development.